Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Finished Goods: 2023-2025

Historic Finished Goods for Tg Therapeutics (TGTX) over the last 3 years, with Sep 2025 value amounting to $21.1 million.

  • Tg Therapeutics' Finished Goods rose 164.86% to $21.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.1 million, marking a year-over-year increase of 164.86%. This contributed to the annual value of $13.9 million for FY2024, which is 597.25% up from last year.
  • According to the latest figures from Q3 2025, Tg Therapeutics' Finished Goods is $21.1 million, which was down 3.46% from $21.8 million recorded in Q2 2025.
  • Over the past 5 years, Tg Therapeutics' Finished Goods peaked at $21.8 million during Q2 2025, and registered a low of $52,000 during Q1 2023.
  • Over the past 3 years, Tg Therapeutics' median Finished Goods value was $2.0 million (recorded in 2023), while the average stood at $7.5 million.
  • Data for Tg Therapeutics' Finished Goods shows a peak YoY skyrocketed of 3,559.62% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows Tg Therapeutics' Finished Goods stood at $2.0 million in 2023, then skyrocketed by 597.25% to $13.9 million in 2024, then spiked by 164.86% to $21.1 million in 2025.
  • Its Finished Goods stands at $21.1 million for Q3 2025, versus $21.8 million for Q2 2025 and $10.7 million for Q1 2025.